Sale

Ophthalmoplegia Market

Ophthalmoplegia Market Size, Trends, Analysis, Forecast: By Type: External Ophthalmoplegia, Internuclear Opthalmoplegia; By Treatment Type: Surgery, Drug Treatment, Others; By End User: Hospital and Clinics, Ambulatory Clinics, Others; Regional Analysis; Market Dynamics: SWOT Analysis; Supplier Landscape; 2024-2032

Ophthalmoplegia Market Outlook

The ophthalmoplegia market size was valued at USD 1032.7 million in 2023, driven by the increasing advancements in healthcare and pharmaceutical industry across the 7 major markets. The market is expected to grow at a CAGR of 8.3% during the forecast period of 2024-2032, with the value likely to reach USD 2130.2 million by 2032.

 

Ophthalmoplegia: Introduction

Ophthalmoplegia is the weakness of the eye muscles, affecting one or more than one of the six muscles holding the eye in place and controlling its movement. It can be further segmented into chronic progressive external ophthalmoplegia and internal ophthalmoplegia. People suffering from ophthalmoplegia may have blurred or double vision, and even misaligned eyes in some cases. It is mostly diagnosed through MRI or CT scans.

 

Ophthalmoplegia Market Analysis

The incidence of ophthalmoplegia is slightly higher in people affected with diabetes. Since the prevalence of diabetes is growing due to the changes in modern lifestyles and unhealthy dietary practices, the ophthalmoplegia market demand has also observed an upswing. Along with diabetes, patients affected by multiple sclerosis or Graves’ disease are also at a risk of developing the condition.

 

With the rising preference for minimally invasive surgical interventions, silicone sling procedure is commonly performed as an ophthalmoplegia treatment. This procedure is used to treat drooping eyelids, a critical symptom of the disease. It is performed with the help of a Seiff silicone suspension and the silicone is guided in the muscle through a stab incision. This procedure offers multiple advantages like early recovery, less surgical time, and no multiple incisions when compared to other methods.

 

Apart from surgical interventions and drugs like tetracycline, corticosteroid treatment, and botulinum toxin, vitamins are also used quite frequently. However, adopting traditional Chinese medicine as a complementary and alternative method, acupuncture is also being investigated as a potential therapeutic method. With a vision to cater to a diverse set of patients, scientists are looking into various approaches, which are poised to boost the ophthalmoplegia market value in the forecast period.


 
Ophthalmoplegia Market Segmentation

Market Breakup by Type

  • External Ophthalmoplegia
  • Internuclear Opthalmoplegia

 

Market Breakup by Treatment Type

  • Surgery
  • Drug Treatment
  • Others

 

Market Breakup by End User

  • Hospital and Clinics
  • Ambulatory Clinics
  • Others

 

Market Breakup by Region

  • United States
  • EU-4 and the United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
  • Japan

 

Ophthalmoplegia Market Overview

North America has been dominating the ophthalmoplegia market share owing to factors like a well-developed healthcare infrastructure and the increased presence of prominent pharmaceutical companies. In addition, companies have been expanding their product portfolios for better patient outcomes.

 

Europe is another major market with a high emphasis on offering better healthcare solutions to patients. With substantial geriatric population, the region may experience more ophthalmoplegia cases in upcoming years. Therefore, there has been significant focus on developing innovative and highly effective treatment alternatives. The rising technical advancements that incorporate artificial intelligence and machine learning into drug development are some of the critical trends shaping the market value in the region.

 

The Asia Pacific is projected to witness significant ophthalmoplegia market growth which can be attributed to rising healthcare investments from the native governments as well as foreign companies. Along with improving the healthcare infrastructure, several influential pharmaceutical companies are setting up new research labs and clinics to put the easily available resources in the area to use.

 

Ophthalmoplegia Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

 

  • F. Hoffmann-La Roche Ltd
  • Bausch Health
  • Johnson & Johnson Services, Inc.
  • Medline Industries
  • Santen Pharmaceutical Co.
  • Novartis AG
  • Abbott
  • Essilor
  • Astellas Pharma Inc.
  • Enzon Pharmaceuticals
  • Amritt, Inc.
  • NIDEK CO.
  • Carl Zeiss AG
  • Santen Pharmaceutical Co.
  • Medline Industries

 

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Type
  • Treatment Type
  • End User
  • Region
Breakup by Type
  • External Ophthalmoplegia
  • Internuclear Opthalmoplegia 
Breakup by Treatment Type
  • Surgery
  • Drug Treatment
  • Others
Breakup by End User
  • Hospital and Clinics
  • Ambulatory Clinics
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • F. Hoffmann-La Roche Ltd
  • Bausch Health
  • Johnson & Johnson Services, Inc.
  • Medline Industries
  • Santen Pharmaceutical Co.
  • Novartis AG
  • Abbott
  • Essilor
  • Astellas Pharma Inc.
  • Enzon Pharmaceuticals
  • Amritt, Inc.
  • NIDEK CO.Carl Zeiss AG
  • Carl Zeiss AG
  • Santen Pharmaceutical Co.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions 
    1.3    Report Coverage – Key Segmentation and Scope  
    1.4    Research Methodology
2    Executive Summary
3    Ophthalmoplegia Overview
 
    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Ophthalmoplegia Epidemiology Analysis – 7MM
    5.1    7MM Epidemiology Scenario Overview (2017-2032)
    5.2    United States Ophthalmoplegia Epidemiology Forecast (2017-2032)
    5.3    EU-4 and United Kingdom Ophthalmoplegia Epidemiology Forecast (2017-2032)
        5.3.1    Germany Ophthalmoplegia Epidemiology Forecast (2017-2032)
        5.3.2    France Ophthalmoplegia Epidemiology Forecast (2017-2032)
        5.3.3    Italy Ophthalmoplegia Epidemiology Forecast (2017-2032)
        5.3.4    Spain Ophthalmoplegia Epidemiology Forecast (2017-2032)
        5.3.5    United Kingdom Ophthalmoplegia Epidemiology Forecast (2017-2032)
    5.4    Japan Ophthalmoplegia Epidemiology Forecast (2017-2032)
6    Ophthalmoplegia Market Overview – 7MM
    6.1    Ophthalmoplegia Market Historical Value (2017-2023) 
    6.2    Ophthalmoplegia Market Forecast Value (2024-2032)
7    Ophthalmoplegia Market Landscape – 7MM
    7.1    Ophthalmoplegia: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Ophthalmoplegia Product Landscape
        7.2.1    Analysis by Treatment Type
        7.2.2    Analysis by Route of Administration
        7.2.3    Analysis by Treatment Type
8    Ophthalmoplegia Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    Ophthalmoplegia Market Dynamics

    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model
    10.4    Key Demand Indicators 
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends  
    10.7    Value Chain Analysis
11    Ophthalmoplegia Market Segmentation – 7MM
    11.1     Ophthalmoplegia Market by Type
        11.1.1    Market Overview
        11.1.2    External Ophthalmoplegia
        11.1.3    Internuclear Opthalmoplegia 
    11.2    Ophthalmoplegia Market by Treatment Type
        11.2.1    Market Overview
        11.2.2    Surgery
        11.2.3    Drug Treatment
        11.2.4    Others
    11.3    Ophthalmoplegia Market by End User 
        11.3.1    Market Overview
        11.3.2    Hospital and Clinics
        11.3.3    Ambulatory Clinics
        11.3.4    Others
    11.4    Ophthalmoplegia Market by Region
        11.4.1    Market Overview
        11.4.2    United States    
        11.4.3    EU-4 and the United Kingdom
            11.4.3.1    Germany
            11.4.3.2    France
            11.4.3.3    Italy
            11.4.3.4    Spain
            11.4.3.5    United Kingdom
        11.4.4    Japan
12    United States Ophthalmoplegia Market
    12.1    Ophthalmoplegia Market Historical Value (2017-2023) 
    12.2    Ophthalmoplegia Market Forecast Value (2024-2032)
    12.3    Ophthalmoplegia Market by Disease Type
    12.4    Ophthalmoplegia Market by Treatment Type
13    EU-4 and United Kingdom Ophthalmoplegia Market
    13.1    Ophthalmoplegia Market Historical Value (2017-2023) 
    13.2    Ophthalmoplegia Market Forecast Value (2024-2032)
    13.3    Germany Ophthalmoplegia Market Overview
        13.3.1    Ophthalmoplegia Market by Disease Type
        13.3.2    Ophthalmoplegia Market by Treatment Type
    13.4    France Ophthalmoplegia Market Overview
        13.4.1    Ophthalmoplegia Market by Disease Type
        13.4.2    Ophthalmoplegia Market by Treatment Type
    13.5    Italy Ophthalmoplegia Market Overview
        13.5.1    Ophthalmoplegia Market by Disease Type
        13.5.2    Ophthalmoplegia Market by Treatment Type
    13.6    Spain Ophthalmoplegia Market Overview
        13.6.1    Ophthalmoplegia Market by Disease Type
        13.6.2    Ophthalmoplegia Market by Treatment Type
    13.7    United Kingdom Ophthalmoplegia Market Overview
        13.7.1    Ophthalmoplegia Market by Disease Type
        13.7.2    Ophthalmoplegia Market by Treatment Type
14    Japan Ophthalmoplegia Market
    14.1    Ophthalmoplegia Market Historical Value (2017-2023) 
    14.2    Ophthalmoplegia Market Forecast Value (2024-2032)
    14.3    Ophthalmoplegia Market by Disease Type
    14.4    Ophthalmoplegia Market by Treatment Type
15    Patent Analysis
    15.1    Analysis by Type of Patent
    15.2    Analysis by Publication year
    15.3    Analysis by Issuing Authority
    15.4    Analysis by Patent Age
15.5    Analysis by CPC Analysis
    15.6    Analysis by Patent Valuation 
    15.7    Analysis by Key Players
16    Grants Analysis
    16.1    Analysis by year
    16.2    Analysis by Amount Awarded
    16.3    Analysis by Issuing Authority
    16.4    Analysis by Grant Application
    16.5    Analysis by Funding Institute
    16.6    Analysis by NIH Departments
    16.7    Analysis by Recipient Organization 
17    Clinical Trials Analysis
    17.1     Analysis by Trial Registration Year
    17.2    Analysis by Trial Status
    17.3    Analysis by Trial Phase
    17.4    Analysis by Therapeutic Area
    17.5    Analysis by Geography
18    Funding Analysis
    18.1    Analysis by Funding Instances
    18.2    Analysis by Type of Funding
    18.3    Analysis by Funding Amount
    18.4    Analysis by Leading Players
    18.5    Analysis by Leading Investors
    18.6    Analysis by Geography
19    Partnership and Collaborations Analysis
    19.1    Analysis by Partnership Instances
    19.2    Analysis by Type of Partnership
    19.3    Analysis by Leading Players
    19.4    Analysis by Geography
20    Supplier Landscape
    20.1    F. Hoffmann-La Roche Ltd
        20.1.1    Financial Analysis
        20.1.2    Product Portfolio
        20.1.3    Demographic Reach and Achievements
        20.1.4    Mergers and Acquisition
        20.1.5    Certifications
    20.2    Bausch Health
        20.2.1    Financial Analysis
        20.2.2    Product Portfolio
        20.2.3    Demographic Reach and Achievements
        20.2.4    Mergers and Acquisition
        20.2.5    Certifications
    20.3    Johnson & Johnson Services, Inc.
        20.3.1    Financial Analysis
        20.3.2    Product Portfolio
        20.3.3    Demographic Reach and Achievements
        20.3.4    Mergers and Acquisition
        20.3.5    Certifications
    20.4    Medline Industries
        20.4.1    Financial Analysis
        20.4.2    Product Portfolio
        20.4.3    Demographic Reach and Achievements
        20.4.4    Mergers and Acquisition
        20.4.5    Certifications
    20.5    Santen Pharmaceutical Co.
        20.5.1    Financial Analysis
        20.5.2    Product Portfolio
        20.5.3    Demographic Reach and Achievements
        20.5.4    Mergers and Acquisition
        20.5.5    Certifications
    20.6    Novartis AG
        20.6.1    Financial Analysis
        20.6.2    Product Portfolio
        20.6.3    Demographic Reach and Achievements
        20.6.4    Mergers and Acquisition
        20.6.5    Certifications
    20.7    Abbott
        20.7.1    Financial Analysis
        20.7.2    Product Portfolio
        20.7.3    Demographic Reach and Achievements
        20.7.4    Mergers and Acquisition
        20.7.5    Certifications
    20.8    Essilor
        20.8.1    Financial Analysis
        20.8.2    Product Portfolio
        20.8.3    Demographic Reach and Achievements
        20.8.4    Mergers and Acquisition
        20.8.5    Certifications
    20.9    Astellas Pharma Inc.
        20.9.1    Financial Analysis
        20.9.2    Product Portfolio
        20.9.3    Demographic Reach and Achievements
        20.9.4    Mergers and Acquisition
        20.9.5    Certifications
    20.10    Enzon Pharmaceuticals
        20.10.1    Financial Analysis
        20.10.2    Product Portfolio
        20.10.3    Demographic Reach and Achievements
        20.10.4    Mergers and Acquisition
        20.10.5    Certifications
    20.11    Amritt, Inc.
        20.11.1    Financial Analysis
        20.11.2    Product Portfolio
        20.11.3    Demographic Reach and Achievements
        20.11.4    Mergers and Acquisition
        20.11.5    Certifications
    20.12    NIDEK CO.
        20.12.1    Financial Analysis
        20.12.2    Product Portfolio
        20.12.3    Demographic Reach and Achievements
        20.12.4    Mergers and Acquisition
        20.12.5    Certifications
    20.13    Carl Zeiss AG
        20.13.1    Financial Analysis
        20.13.2    Product Portfolio
        20.13.3    Demographic Reach and Achievements
        20.13.4    Mergers and Acquisition
        20.13.5    Certifications
    20.14    Santen Pharmaceutical Co.
        20.14.1    Financial Analysis
        20.14.2    Product Portfolio
        20.14.3    Demographic Reach and Achievements
        20.14.4    Mergers and Acquisition
        20.14.5    Certifications
21    Ophthalmoplegia Market - Distribution Model (Additional Insight)
    21.1    Overview 
        21.2    Potential Distributors 
        21.3    Key Parameters for Distribution Partner Assessment 
22    Key Opinion Leaders (KOL) Insights (Additional Insight)
23    Company Competitiveness Analysis (Additional Insight)

    23.1    Very Small Companies
    23.2    Small Companies
    23.3    Mid-Sized Companies
    23.4    Large Companies
    23.5    Very Large Companies
24    Payment Methods (Additional Insight)
    24.1    Government Funded
    24.2    Private Insurance
    24.3    Out-of-Pocket


*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The market attained a value of about USD 1032.7 million in 2023, driven by the growing technical advances in medical and pharmaceutical industry.

The market is anticipated to grow at a CAGR of 8.3% during the forecast period of 2024-2032, likely to reach a market value of USD 2130.2 million by 2032.

The market is driven by the rising prevalence of diabetes and multiple sclerosis, which can be considered as a major risk to be affected from ophthalmoplegia. 

The major market trend revolves around the increasing adoption of traditional medicine alternatives like acupuncture to treat a diverse set of symptoms affecting the patients. The Asia-Pacific region is poised to witness substantial market growth in the forecast period.

Based on treatment types, the market is divided into surgery, drug treatment and others.

Major end users include hospitals, clinics, ambulatory clinics, and others.

Based on types, ophthalmoplegia can be divided into external and internuclear ophthalmoplegia.      

The major regions of the market include the United States, Japan, EU-4 which is segmented into Germany, France, Italy, Spain, and the United Kingdom. 

Key players involved in the market are F. Hoffmann-La Roche Ltd, Bausch Health, Johnson & Johnson Services, Inc., Medline Industries, Santen Pharmaceutical Co., Novartis AG, Abbott, Essilor, Astellas Pharma Inc., Amritt, Inc., NIDEK CO., Carl Zeiss AG, Santen Pharmaceutical Co., and Enzon Pharmaceuticals.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER